A Chinese inactivated vaccine against Omicron variants was approved for clinical trials by the National Medical Products Administration on Tuesday. The vaccine, developed by the China National Biotec Group affiliated with Sinopharm, has been under research since December 2021, the company said.
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3